Reviewers: Komal Arora, M.D., (see Reviewers page)
Revised: 22 June 2012, last major update July 2012
Copyright: (c) 2003-2012, PathologyOutlines.com, Inc.
See also Stromal proliferation of uncertain malignant potential, Stromal sarcomas
● Mean age 54, peak incidence in 50’s and 60’s (Am J Surg Pathol 1998;22:148)
● Usually presents with urinary retention
● Also abnormal digital rectal examination, hematuria or hematospermia, palpable rectal mass
● Includes phyllodes tumors
● 31 year old with stromal sarcoma with rhabdoid features (Ann Diagn Pathol 2010;14:453)
● 52 year old with recurrent tumor (J Clin Pathol 2007;60:330)
● 71 year old with urinary obstruction (Case Reports in Pathology 2011;2011 (Article ID 252805))
● Greater cellularity, mitoses, necrosis, and stromal overgrowth than tumors of “uncertain malignant potential”
● Either pure stromal elements or stromal elements with benign glands resembling malignant breast phyllodes tumors
● Vimentin (100%), CD34 (100%), progesterone receptor (85%), desmin (50%), smooth muscle actin (33%), HHF-35 (25%)
● S100 (100%), ER (usually)
● Stromal proliferation of uncertain malignant potential
End of Prostate > Other malignancies > Stromal sarcomas
This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must be interpreted in the context of a patient's clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician.
All information on this website is protected by copyright of PathologyOutlines.com, Inc. Information from third parties may also be protected by copyright. Please contact us at [email protected] with any questions (click here for other contact information).